DEF: Lifecore Biomedical Seeks Stockholder Approval to Eliminate Conversion Limit on Series A Preferred Stock

Lifecore Biomedical is holding a special meeting of stockholders to approve the issuance of shares underlying Series A Convertible Preferred Stock, aiming to remove a conversion limit and potentially increase the voting power of preferred stockholders.

Summary

• Lifecore Biomedical is seeking stockholder approval at a special meeting on April 10, 2025, to eliminate the Exchange Limit on the conversion of Series A Preferred Stock into common stock.
• The Exchange Limit currently restricts the conversion of Series A Preferred Stock if it would result in the issuance of common stock exceeding 19.99% of the outstanding common stock as of January 9, 2023.
• Approval of the Issuance Proposal would allow for the full conversion of the Series A Preferred Stock, potentially increasing the voting power of the preferred stockholders.
• The company issued 38,750 shares of Series A Preferred Stock on January 9, 2023, for $38.75 million to support working capital and liquidity needs.
• The initial conversion price was $7.00 per share, but it was adjusted to $6.53 per share following a private placement in October 2024.
• The Board of Directors recommends voting in favor of the Issuance Proposal and an Adjournment Proposal to allow for additional proxy solicitation if needed.
• The holders of Series A Preferred Stock currently control approximately 41.38% of the voting power.
• If the Issuance Proposal is approved, the holders of Series A Preferred Stock would gain voting power in 818,790 shares of Common Stock for a total of a 42.48% share of voting power in the Company, or a 1.10% increase from their current voting power, based on the shares outstanding as of February 18, 2025.
• The approval of the Issuance Proposal would also result in an aggregate decrease in voting power of all stockholders other than holders of the Series A Preferred Stock of approximately 1.10%.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily focused on outlining the details of the proposals and the mechanics of the special meeting. The investor dispute introduces a slightly negative element, but the overall sentiment is balanced.

Positives

• Approval of the Issuance Proposal would remove the Exchange Limit, potentially simplifying the capital structure.
• The Series A Financing Transaction provided $38.75 million to support working capital and liquidity needs.
• The Board believes the terms of the Series A Preferred Stock were reasonable given the company's needs at the time.

Negatives

• Approval of the Issuance Proposal would result in dilution of existing common stockholders' percentage ownership and voting power.
• The voting power may become further centralized with the holders of the Series A Preferred Stock, which may also have an incidental anti-takeover effect and/or discourage the possibility of, or render more difficult, certain mergers, tender offers, proxy contests or other change of control or ownership transactions.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal could materially and adversely affect the company's ability to obtain additional capital under similar terms in the future.
• Future issuances of shares of Common Stock upon conversion of the Series A Preferred Stock, if any, may cause a significant reduction in the percentage economic interests of our current stockholders, and could cause the market price of our Common Stock to decline.
• An investor dispute exists with 22NW Fund, L.P., which has filed a complaint against the company, two former officers, and five former or current directors.

Future Outlook

The company intends to continue using its best efforts to obtain stockholder approval under Nasdaq Rule 5635(d), including by calling additional meetings of stockholders, until it obtains the requisite approval.

Management Comments

• Our Board of Directors has approved the Issuance Proposal and the Adjournment Proposal set forth in the proxy statement and recommends that you vote in favor of such proposals.

Industry Context

Many companies utilize preferred stock to raise capital, often with conversion features that can impact the company's capital structure and voting control. The need for stockholder approval to exceed certain issuance thresholds is a common requirement under Nasdaq listing rules.

Comparison to Industry Standards

• The terms of the Series A Preferred Stock, including the dividend rate and conversion features, appear to be within the range of similar financing transactions in the biotech industry.
• The 19.99% Exchange Limit is a standard provision to avoid triggering Nasdaq Listing Rule 5635(d) without stockholder approval.
• The legal proceedings are not uncommon for companies with complex financing arrangements and activist investors.

Legal Proceedings

• 22NW Fund, L.P. filed a complaint against the company, two former officers, and five former or current directors seeking money damages and specific performance under the Purchase Agreement.
• The company and the individual defendants filed a motion to dismiss the complaint on February 24, 2025, and the Court has scheduled a case management conference for March 27, 2025.

Stakeholder Impact

• Approval of the Issuance Proposal could dilute the ownership and voting power of existing common stockholders.
• The outcome of the vote will impact the company's ability to access capital and potentially influence its strategic direction.

Next Steps

• Stockholders are encouraged to vote on the Issuance Proposal and the Adjournment Proposal.
• The Special Meeting will be held virtually on April 10, 2025.
• The company will announce preliminary voting results at the Special Meeting and publish results in a Form 8-K.

Key Dates